DURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the ...

Not long after SARS-CoV-2 was first identified in December 2019 as the cause of an alarming cluster of severe pneumonia cases in central China, the U.S. Centers for Disease Control and Prevention ...

ENFIELD, Conn.--(BUSINESS WIRE)--Eppendorf is proud to announce they have received Connecticut State approval to conduct Biosafety Level 2 (BL2) infectious disease related research. This greatly ...